SecBot SecBot
8-K ·Filed Apr 3, 2026

ABBV

AbbVie Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001551152-26-000011
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming Q1 2026 earnings for confirmation of the $744 million IPR&D expense and final EPS results; the updated guidance range implies slightly lower profitability expectations for the year.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$204.99
T+0 close · Apr 3, 2026 · via day close
Latest settled
+22.47%
T+60 · $251.06
Vs SPY
+9.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $204.99entry
  2. T+1 · 7mo ago −0.15%α −0.22% · $204.67
  3. T+5 · 7mo ago −0.11%α −4.24% · $204.77
  4. T+20 · 7mo ago +1.55%α −7.44% · $208.16
  5. T+60 · 5mo ago +22.47%α +9.01% · $251.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbbVie updated its 2026 adjusted diluted EPS guidance to $13.96–$14.16, incorporating a $0.41 per share impact from Q1 2026 acquired IPR&D and milestones expense. This follows the company's prior full-year guidance of $14.37–$14.57, which excluded such expenses.

Key Facts

  • AbbVie issued updated 2026 full-year adjusted diluted EPS guidance of $13.96–$14.16, down from prior range of $14.37–$14.57
  • The reduction reflects a $0.41 per share impact from acquired IPR&D and milestones expense incurred in Q1 2026
  • The company does not forecast future IPR&D or milestones expenses due to uncertainty in timing and occurrence
  • This filing provides preliminary estimates; final results are subject to closing procedures

Financial Impact

Full-year adjusted EPS guidance reduced by $0.41 to $13.96–$14.16, reflecting $744 million in Q1 2026 acquired IPR&D and milestones expense

epsguidance

Risk Factors

  • Future IPR&D and milestones expenses remain uncertain and could further impact earnings
  • Preliminary estimates are subject to change upon final financial closing

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
72% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001551152-26-000011
Document: abbv-20260331nonxgaapxex991.htm0001551152-26-000011
Document: 0001551152-26-000011-index-headers.html0001551152-26-000011
Document: 0001551152-26-000011-index.html0001551152-26-000011
Document: 0001551152-26-000011.txt0001551152-26-000011
8-K Data (Synthetic)0001551152-26-000011

Track record

22 reports on ABBV

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (11h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026